These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 26158339)

  • 1. Type II Inhibitors Targeting CDK2.
    Alexander LT; Möbitz H; Drueckes P; Savitsky P; Fedorov O; Elkins JM; Deane CM; Cowan-Jacob SW; Knapp S
    ACS Chem Biol; 2015 Sep; 10(9):2116-25. PubMed ID: 26158339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conformational analysis of the DFG-out kinase motif and biochemical profiling of structurally validated type II inhibitors.
    Vijayan RS; He P; Modi V; Duong-Ly KC; Ma H; Peterson JR; Dunbrack RL; Levy RM
    J Med Chem; 2015 Jan; 58(1):466-79. PubMed ID: 25478866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure of cyclin-dependent kinase 2 (CDK2) in complex with the specific and potent inhibitor CVT-313.
    Talapati SR; Nataraj V; Pothuganti M; Gore S; Ramachandra M; Antony T; More SS; Krishnamurthy NR
    Acta Crystallogr F Struct Biol Commun; 2020 Aug; 76(Pt 8):350-356. PubMed ID: 32744246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and Characterization of an Irreversible Inhibitor of CDK2.
    Anscombe E; Meschini E; Mora-Vidal R; Martin MP; Staunton D; Geitmann M; Danielson UH; Stanley WA; Wang LZ; Reuillon T; Golding BT; Cano C; Newell DR; Noble ME; Wedge SR; Endicott JA; Griffin RJ
    Chem Biol; 2015 Sep; 22(9):1159-64. PubMed ID: 26320860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lead Discovery of Type II BRAF V600E Inhibitors Targeting the Structurally Validated DFG-Out Conformation Based upon Selected Fragments.
    Zhang Q; Zhang X; You Q
    Molecules; 2016 Jul; 21(7):. PubMed ID: 27438814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insights on Structural Characteristics and Ligand Binding Mechanisms of CDK2.
    Li Y; Zhang J; Gao W; Zhang L; Pan Y; Zhang S; Wang Y
    Int J Mol Sci; 2015 Apr; 16(5):9314-40. PubMed ID: 25918937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulating the interaction between CDK2 and cyclin A with a quinoline-based inhibitor.
    Deng Y; Shipps GW; Zhao L; Siddiqui MA; Popovici-Muller J; Curran PJ; Duca JS; Hruza AW; Fischmann TO; Madison VS; Zhang R; McNemar CW; Mayhood TW; Syto R; Annis A; Kirschmeier P; Lees EM; Parry DA; Windsor WT
    Bioorg Med Chem Lett; 2014 Jan; 24(1):199-203. PubMed ID: 24332088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From Type I to Type II: Design, Synthesis, and Characterization of Potent Pyrazin-2-ones as DFG-Out Inhibitors of PDGFRβ.
    Bethke E; Pinchuk B; Renn C; Witt L; Schlosser J; Peifer C
    ChemMedChem; 2016 Dec; 11(24):2664-2674. PubMed ID: 27885822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An integrated chemical biology approach provides insight into Cdk2 functional redundancy and inhibitor sensitivity.
    Echalier A; Cot E; Camasses A; Hodimont E; Hoh F; Jay P; Sheinerman F; Krasinska L; Fisher D
    Chem Biol; 2012 Aug; 19(8):1028-40. PubMed ID: 22921070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors.
    Nandha Premnath P; Craig S; McInnes C
    J Vis Exp; 2015 Oct; (105):e52441. PubMed ID: 26554946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural and binding studies of cyclin-dependent kinase 2 with NU6140 inhibitor.
    Talapati SR; Goyal M; Nataraj V; Pothuganti M; R SM; Gore S; Ramachandra M; Antony T; More SS; Rao NK
    Chem Biol Drug Des; 2021 Nov; 98(5):857-868. PubMed ID: 34423559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting inactive conformations of protein kinases using active structures: conformational selection of type-II inhibitors.
    Xu M; Yu L; Wan B; Yu L; Huang Q
    PLoS One; 2011; 6(7):e22644. PubMed ID: 21818358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-based approaches to improve selectivity: CDK2-GSK3beta binding site analysis.
    Vulpetti A; Crivori P; Cameron A; Bertrand J; Brasca MG; D'Alessio R; Pevarello P
    J Chem Inf Model; 2005; 45(5):1282-90. PubMed ID: 16180905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure and inhibitor specificity of the PCTAIRE-family kinase CDK16.
    Dixon-Clarke SE; Shehata SN; Krojer T; Sharpe TD; von Delft F; Sakamoto K; Bullock AN
    Biochem J; 2017 Feb; 474(5):699-713. PubMed ID: 28057719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitor Selectivity for Cyclin-Dependent Kinase 7: A Structural, Thermodynamic, and Modelling Study.
    Hazel P; Kroll SH; Bondke A; Barbazanges M; Patel H; Fuchter MJ; Coombes RC; Ali S; Barrett AG; Freemont PS
    ChemMedChem; 2017 Mar; 12(5):372-380. PubMed ID: 28125165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Effect of Conformational Flexibility on Binding Free Energy Estimation between Kinases and Their Inhibitors.
    Araki M; Kamiya N; Sato M; Nakatsui M; Hirokawa T; Okuno Y
    J Chem Inf Model; 2016 Dec; 56(12):2445-2456. PubMed ID: 28024406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Conformational Activation of CDK2 Kinase.
    Pellerano M; Tcherniuk S; Perals C; Ngoc Van TN; Garcin E; Mahuteau-Betzer F; Teulade-Fichou MP; Morris MC
    Biotechnol J; 2017 Aug; 12(8):. PubMed ID: 28430399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential binding of inhibitors to active and inactive CDK2 provides insights for drug design.
    Kontopidis G; McInnes C; Pandalaneni SR; McNae I; Gibson D; Mezna M; Thomas M; Wood G; Wang S; Walkinshaw MD; Fischer PM
    Chem Biol; 2006 Feb; 13(2):201-11. PubMed ID: 16492568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular dynamics simulation and free energy calculation studies of kinase inhibitors binding to active and inactive conformations of VEGFR-2.
    Wu X; Wan S; Wang G; Jin H; Li Z; Tian Y; Zhu Z; Zhang J
    J Mol Graph Model; 2015 Mar; 56():103-12. PubMed ID: 25594497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclin-Dependent Kinase 2 in Cellular Senescence and Cancer. A Structural and Functional Review.
    Volkart PA; Bitencourt-Ferreira G; Souto AA; de Azevedo WF
    Curr Drug Targets; 2019; 20(7):716-726. PubMed ID: 30516105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.